Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein AI: potential reverse cholesterol transport in humans

M Eriksson, LA Carlson, TA Miettinen, B Angelin - Circulation, 1999 - Am Heart Assoc
M Eriksson, LA Carlson, TA Miettinen, B Angelin
Circulation, 1999Am Heart Assoc
Background—Apolipoprotein (apo) AI is the major protein component of HDL, a cholesterol
transport particle that protects against atherosclerosis. Apo AI is believed to promote reverse
cholesterol transport, transferring cholesterol from peripheral cells to the liver for subsequent
elimination. To test this hypothesis in humans, we measured fecal steroid excretion before
and after the intravenous infusion of human proapo AI (precursor of apo AI) liposome
complexes. Methods and Results—Four subjects with heterozygous familial …
Background—Apolipoprotein (apo) A-I is the major protein component of HDL, a cholesterol transport particle that protects against atherosclerosis. Apo A-I is believed to promote reverse cholesterol transport, transferring cholesterol from peripheral cells to the liver for subsequent elimination. To test this hypothesis in humans, we measured fecal steroid excretion before and after the intravenous infusion of human proapo A-I (precursor of apo A-I) liposome complexes.
Methods and Results—Four subjects with heterozygous familial hypercholesterolemia were studied under standardized conditions. The fecal excretion of bile acids and neutral sterols was determined for 9 days before and 9 days after an intravenous infusion of recombinant human proapo A-I (4 g protein) liposome complexes. Plasma apoA-I and HDL cholesterol levels increased transiently (mean peak concentrations were 64% and 35% above baseline, respectively) during the first 24 hours. Mean lipoprotein lipid and apolipoprotein levels were not different during the 2 collecting periods, however. Serum lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, was also unchanged. The fecal excretion of cholesterol (neutral sterols and bile acids) increased in all subjects (mean increase, +39% and +30%, respectively), corresponding to the removal of ≈500 mg/d excess cholesterol after infusion. Control infusions with only liposomes in 2 of the patients did not influence lipoprotein pattern or cholesterol excretion.
Conclusions—Infusion of proapoA-I liposomes in humans promotes net cholesterol excretion from the body, implying a stimulation of reverse cholesterol transport. This mechanism may prove useful in the treatment of atherosclerosis.
Am Heart Assoc